These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12192774)

  • 21. Drug-eluting stents.
    Rinfret S; Schampaert E
    CMAJ; 2007 May; 176(11):1611-2. PubMed ID: 17515589
    [No Abstract]   [Full Text] [Related]  

  • 22. Preparing for the introduction of new technologies: who is going to pay for them?
    Marshall PR
    J Cardiovasc Manag; 2002; 13(1):14-20. PubMed ID: 11828780
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug-eluting coronary stents].
    Fontos G
    Orv Hetil; 2006 Oct; 147(43):2059-66. PubMed ID: 17297752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-eluting stent fracture and acute coronary syndrome.
    Chhatriwalla AK; Cam A; Unzek S; Bhatt DL; Raymond RE; Lincoff AM; Whitlow PL; Ellis SG; Tuzcu EM; Kapadia SR
    Cardiovasc Revasc Med; 2009; 10(3):166-71. PubMed ID: 19595398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
    Lau KW; Johan A; Sigwart U; Hung JS
    Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing treatment patterns for coronary artery revascularization in Canada: the projected impact of drug eluting stents.
    Halpern MT; Lacey M; Clark MA; Valentin MA
    BMC Cardiovasc Disord; 2004 Dec; 4():23. PubMed ID: 15596004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Learning new lines. New 'playbook' advises hospitals how to win bigger reimbursement for medical procedures that use expensive advanced technology.
    Taylor M
    Mod Healthc; 2003 Jul; 33(30):6-7, 1. PubMed ID: 12929254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Potential impact of drug-eluting stents in Sicily: results from a multicenter survey and cost-benefit analysis of drug-eluting stents versus bare metal stents].
    Gulizia M; Martelli E; Tamburino C; Tolaro S; Frasheri A; Giambanco F; Grassi R; Fiscella A; Milazzo D
    Ital Heart J Suppl; 2004 Aug; 5(8):630-8. PubMed ID: 15554018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the impact of drug-eluting stents. Hospitals must be prepared to absorb a potentially negative financial impact.
    Pfeiffer H
    Healthc Exec; 2003; 18(4):60-1. PubMed ID: 12841062
    [No Abstract]   [Full Text] [Related]  

  • 32. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of drug-eluting stents in coronary angioplasty.
    Santos R; Pereira H
    Rev Port Cardiol; 2005 Nov; 24(11):1409-18. PubMed ID: 16463989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A one-year comparison of cost and outcomes of angioplasty in stent and nonstent patients.
    Sen SS; Khandker RK; Roth DA; Thomas J
    Am J Ther; 2005; 12(3):210-7. PubMed ID: 15891263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. eComment: Costs of percutaneous coronary intervention versus coronary artery bypass surgery.
    Almeida RM
    Interact Cardiovasc Thorac Surg; 2009 Jun; 8(6):672. PubMed ID: 19443497
    [No Abstract]   [Full Text] [Related]  

  • 36. Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease.
    Hlatky MA; Melsop KA; Boothroyd DB;
    Am J Cardiol; 2006 Jun; 97(12A):59G-65G. PubMed ID: 16813739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary artery bypass graft vs. percutaneous coronary angioplasty: CABG on the rebound?
    Taggart DP
    Curr Opin Cardiol; 2007 Nov; 22(6):517-23. PubMed ID: 17921738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymers, drug release, and drug-eluting stents.
    Commandeur S; van Beusekom HM; van der Giessen WJ
    J Interv Cardiol; 2006 Dec; 19(6):500-6. PubMed ID: 17107364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
    Iijima R; Mehilli J; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.